Related Articles

News
STAT+: Gilead drug prolongs survival of women with common form of breast cancer
September 7, 2022
San Francisco Biotechnology Network News
News
Comments Off on STAT+: Gilead drug prolongs survival of women with common form of breast cancer
Gilead Sciences said its cancer drug Trodelvy prolonged the survival of women with the most common form of breast cancer by just under 30%. […]

News
STAT+: Pharmalittle: FDA user-fee reauthorization bill hits a snag; USPTO takes a tougher stand toward drugmakers
July 19, 2022
San Francisco Biotechnology Network News
News
Comments Off on STAT+: Pharmalittle: FDA user-fee reauthorization bill hits a snag; USPTO takes a tougher stand toward drugmakers
People who work at biotechs, life sciences firms, and drugmakers pull in the largest salaries of anyone in health care — usually more than $100,000 per year. […]

News
STAT+: Medicare Advantage-focused Oak Street, Agilon Health chart out growth at J.P. Morgan
January 10, 2023
San Francisco Biotechnology Network News
News
Comments Off on STAT+: Medicare Advantage-focused Oak Street, Agilon Health chart out growth at J.P. Morgan
Medicare Advantage providers Oak Street & Agilon Health chart out ambitious growth on day one of #JPM23. […]